Australia's Mayne Pharma surges on $408 million takeover by Hungary's Gedeon Richter

By Reuters News

** Shares of Australia's Mayne Pharma MYX.AX soar as much as 86% to A$5.970, marking their biggest intraday pct gain ever

** Shares hit their highest level since late November 2025

** Pharma firm enters scheme implementation deed with Hungarian drugmaker Gedeon Richter GDRB.BU under which the latter will buy 100% of MYX

** Offer values the company's equity at about A$604 million ($407.76 million) and represents a 99.4% premium to its last close on November 16

** Co says scheme is subject to completing sale of its international business segment to Evaris Pharma

** More than 1.2 million shares change hands, about 4.6x the 30-day average

** YTD, stock up 86.8%, including session's moves


($1 = 1.4813 Australian dollars)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.